Thank you for voting Crowdsignal Logo

Which management strategy should be recommended for this patient's bone health?

  •  
     
  •  
     
  •  
     
  •  
     
Total Votes: 241
1 Comment

  • An oncology nurse - 12 years ago

    Why wouldn't the answer be initiate calcium, vit D, get DEXA, AND start on subQ denosumab since aromatase inhibitors can cause a significant decrease in BMD within the first year of therapy? Research has shown calcium and vit D isn't enough to prevent the BMD decrease and therefore the fracture risk when patients are on AI's

Leave a Comment

0/4000 chars


Submit Comment

Create your own.

Opinions! We all have them. Find out what people really think with polls and surveys from Crowdsignal.